Urine cell-free RNA test detects bladder cancer and predicts BCG response
Prospective · Nat Med · 2026-10-04. Number 2 in the UrologyWatch Top 5 for October 4, 2026.
A new urine cfRNA sequencing method (uRARE-seq) showed 95% sensitivity at 90% specificity for localized bladder cancer detection across 683 samples, outperformed urine tumor DNA analysis, and distinguished BCG responders from non-responders with an AUC of 0.93.
Why it matters: Could offer a noninvasive tool to detect recurrence and predict BCG response, pending prospective validation.
Source: Nat Med · PubMed 42827132 · DOI 10.1016/j.ccell.2022.12.005
Loading today's edition…